Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S85-S92

  Ruixo, Juan Jose Perez ^a   Doshi, Sameer ^a   Sohn, Winnie ^a   Chow, Andrew ^a  

^a AMGEN INC   (United States)

Author keywords

cancer; denosumab; modelling; pharmacodynamics; pharmacokinetics

Indexed keywords

BIOLOGICAL MARKER; DENOSUMAB; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

BONE METASTASIS; CANCER PATIENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG SAFETY; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; OSTEOCLAST; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL (TOPIC); QUANTITATIVE ANALYSIS; REVIEW; SIMULATION; SOLID TUMOR; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; SECONDARY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; BONE RESORPTION; HUMANS; RANK LIGAND;

EID: 84923378640     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.388     Document Type: Review

References (45)

1. Coleman RE,. Skeletal complications of malignancy. Cancer. 1997; 80 (8 Suppl): 1588-1594.
2. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE,. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer. 2003; 89 (11): 2031-2037.
3. Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999; 145 (3): 527-538.
4. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93 (2): 165-176.
5. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998; 95 (7): 3597-3602.
6. Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009; 24 (2): 182-195.
7. Gibiansky L, Sutjandra L, Doshi S, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumors. Clin Pharmacokinet. 2012; 51 (4): 247-260.
8. Doshi S, Sutjandra L, Zheng J, et al. Denosumab dose selection for patients with bone matastases from solid tumors. Clin Cancer Res. 2012; 18 (9): 1-10.
9. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28 (35): 5132-5139.
10. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377 (9768): 813-822.
11. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-bind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29 (9): 1125-1132.
12. Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetics meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet. 2011; 50 (12): 793-807.
13. Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the target mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008; 35: 573-591.
14. Porter CJ, Charman SA,. Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci. 2000; 89 (3): 297-310.
15. Swartz MA,. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001; 50 (1-2): 3-20.
16. Kagan L, Gershkovich P, Mendelman A, Amsili S, Ezov N, Hoffman A,. The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm. 2007; 67 (3): 759-765.
17. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH,. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49: 493-507.
18. Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA,. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet. 2011; 50 (2): 131-142.
19. Dirks NL, Meibohm B,. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49 (10): 633-659.
20. Kakkar T, Sung C, Gibiansky L, et al. IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Population PK. 2011; 28 (10): 2530-2542.
21. Olsson-Gisleskog P, Jacqmin P, Perez-Ruixo JJ,. Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects. Clin Pharmacokinet. 2007; 46 (2): 159-173.
22. Roskos LK, Davis CG, Schwab GM,. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res. 2004; 61 (3): 108-120.
23. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354 (8): 821-831.
24. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008; 43 (2): 222-229.
25. Wang W, Wang EQ, Balthasar JP,. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008; 84 (5): 548-558.
26. Sohn W, Simiens MA, Jaeger K, Hutton S, Jang G,. The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. Br J Clin Pharmacol. 2014; 78 (3): 477-487.
27. Block GA, Bone HG, Fang L, Lee E, Padhi D,. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012; 27 (7): 1471-1479.
28. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005; 97 (1): 59-69.
29. Lipton A, Costa L, Ali SM, Demers LM,. Bone markers in the management of metastatic bone disease. Cancer Treat Rev. 2001; 27 (3): 181-185.
30. Costa L, Demers LM, Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol. 2002; 20 (3): 850-856.
31. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A,. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem. 1995; 41 (10): 1489-1494.
32. Demers LM, Costa L, Lipton A,. Biochemical markers and skeletal metastases. Cancer. 2000; 88 (12 suppl): 2919-2926.
33. Brown JE, Thomson CS, Ellis SP, Gutcher SA, Purohit OP, Coleman RE,. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer. 2003; 89 (11): 2031-2037.
34. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005; 23 (22): 4925-4935.
35. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998; 16 (6): 2038-2044.
36. Body JJ, Facon T, Coleman RE,. et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006; 12 (4): 1221-1228.
37. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007; 25 (28): 4431-4437.
38. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasm after intravenous bisphosphonates. J Clin Oncol. 2009; 27 (10): 1564-1571.
39. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010; 28 (35): 5132-5139.
40. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377 (9768): 813-822.
41. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-bind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011; 29 (9): 1125-1132.
42. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012; 48 (16): 3082-3092.
43. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME,. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2013; 39 (1): 97-104.
44. Sun L, Yu S,. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases. a systematic review and meta-analysis. Am J Clin Oncol. 2013; 36 (4): 399-403.
45. Meibohm B,. Population pharmacokinetic/pharmacodynamic analyses as the basis for dosing of therapeutic monoclonal antiboides. Clin Pharmacokinet. 2011; 50 (12): 823-824.